William G. Herrington
A5078477384- Chronic Kidney Disease and Diabetes
- Diabetes Treatment and Management
- Dialysis and Renal Disease Management
- Blood Pressure and Hypertension Studies
- Lipoproteins and Cardiovascular Health
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Systems, Economic Evaluations, Quality of Life
- Renal and Vascular Pathologies
- Potassium and Related Disorders
- Metabolism, Diabetes, and Cancer
- Diabetes Management and Research
- Chronic Disease Management Strategies
- Parathyroid Disorders and Treatments
- Renal Diseases and Glomerulopathies
- Pancreatic function and diabetes
- COVID-19 Clinical Research Studies
- Heart Failure Treatment and Management
- Renal Transplantation Outcomes and Treatments
- Hormonal Regulation and Hypertension
- Pharmaceutical Economics and Policy
- Electrolyte and hormonal disorders
- Liver Disease Diagnosis and Treatment
- Genetic Associations and Epidemiology
- Obesity, Physical Activity, Diet
- Hemodynamic Monitoring and Therapy
University of Oxford
2016-2025
Oxford University Hospitals NHS Trust
2012-2025
Medical Research Council
2016-2024
MRC Clinical Trials Unit at UCL
2013-2024
Chinese Academy of Medical Sciences & Peking Union Medical College
2022-2024
Heidelberg University
2022-2024
University Hospital Heidelberg
2022-2024
Nuffield Health
2016-2024
National Health and Medical Research Council
2024
National Kidney Foundation
2023
This article is published as part of a supplement sponsored by Kidney Disease: Improving Global Outcomes (KDIGO). The opinions or views expressed in this are those the authors and do not necessarily reflect recommendations International Society Nephrology Elsevier. Dosages, indications, methods use for products that referred to may their clinical experience be derived from professional literature other sources.
The effects of empagliflozin in patients with chronic kidney disease who are at risk for progression not well understood. EMPA-KIDNEY trial was designed to assess the treatment a broad range such patients.
The ESC Guidelines represent the views of and were produced after careful consideration scientific medical knowledge evidence available at time their publication.The is not responsible in event any contradiction, discrepancy, and/or ambiguity between other official recommendations or guidelines issued by relevant public health authorities, particular relation to good use healthcare therapeutic strategies.Health professionals are encouraged take fully into account when exercising clinical...
<h3>Importance</h3> In China, diabetes prevalence has increased substantially in recent decades, but there are no reliable estimates of the excess mortality currently associated with diabetes. <h3>Objectives</h3> To assess proportional and estimate diabetes-related absolute rural urban areas China. <h3>Design, Setting, Participants</h3> A 7-year nationwide prospective study 512 869 adults aged 30 to 79 years from 10 (5 5 urban) regions who were recruited between June 2004 July 2008 followed...
BackgroundAmong asymptomatic patients with severe carotid artery stenosis but no recent stroke or transient cerebral ischaemia, either stenting (CAS) endarterectomy (CEA) can restore patency and reduce long-term risks. However, from national registry data, each option causes about 1% procedural risk of disabling death. Comparison their protective effects requires large-scale randomised evidence.MethodsACST-2 is an international multicentre trial CAS versus CEA among thought to require...
Most large, prospective studies of the effects diabetes on mortality have focused high-income countries where patients access to reasonably good medical care and can receive treatments establish maintain glycemic control. In those countries, less than doubles rate death from any cause. Few been conducted in middle-income obesity become common control may be poor.
Sacubitril/valsartan reduces the risk of cardiovascular mortality among patients with heart failure reduced ejection fraction, but its effects on kidney function and cardiac biomarkers in people moderate to severe chronic disease are unknown.The UK HARP-III trial (United Kingdom Heart Renal Protection-III), a randomized double-blind trial, included 414 participants an estimated glomerular filtration rate (GFR) 20 60 mL/min/1.73 m2 who were randomly assigned sacubitril/valsartan 97/103 mg...
Abstract Aims To develop and validate a recalibrated prediction model (SCORE2-Diabetes) to estimate the 10-year risk of cardiovascular disease (CVD) in individuals with type 2 diabetes Europe. Methods results SCORE2-Diabetes was developed by extending SCORE2 algorithms using individual-participant data from four large-scale datasets comprising 229 460 participants (43 706 CVD events) without previous CVD. Sex-specific competing risk-adjusted models were used including conventional factors...
ABSTRACT Background The effects of the sodium-glucose co-transporter 2 inhibitor empagliflozin on renal and cardiovascular disease have not been tested in a dedicated population people with chronic kidney (CKD). Methods EMPA-KIDNEY trial is an international randomized, double-blind, placebo-controlled assessing whether 10 mg daily decreases risk progression or death CKD. People without diabetes mellitus (DM) were eligible provided they had estimated glomerular filtration rate (eGFR) ≥20 but...
The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Evaluation and Management of Chronic Disease (CKD) updates KDIGO 2012 guideline has been developed with patient partners, clinicians, researchers around world, using robust methodology. This update, based on a substantially broader base evidence than previously available, reflects an exciting time in nephrology. New therapies strategies have tested large diverse populations that help to inform care;...
Previous meta-analyses of summary data from randomised controlled trials have shown that statin therapy increases the risk diabetes, but less is known about size or timing this effect, who at greatest risk. We aimed to address these gaps in knowledge through analysis individual participant large, long-term, randomised, double-blind therapy.
Lowering LDL cholesterol reduces the risk of developing atherosclerotic events in CKD, but effects such treatment on progression kidney disease remain uncertain. Here, 6245 participants with CKD (not dialysis) were randomly assigned to simvastatin (20 mg) plus ezetimibe (10 daily or matching placebo. The main prespecified renal outcome was ESRD (defined as initiation maintenance dialysis transplantation). During 4.8 years follow-up, allocation resulted an average difference (SEM) 0.96 (0.02)...
Despite the high costs of treatment people with kidney disease and associated comorbid conditions, amount reliable information available to guide care such patients is very limited. Some treatments have been assessed in randomized trials, but most trials too small detect effects a magnitude that would be realistic achieve single intervention. Therefore, KDIGO convened an international, multidisciplinary controversies conference titled "Challenges Conduct Clinical Trials Nephrology" identify...